Osteoporosis Drug A Milestone
The Food and Drug Administration Monday approved the first nonhormonal drug to treat osteoporosis, a progressive and often crippling bone disease that may afflict as many as 25 million Americans.
The approval offers the first drug alternative to hormone replacement therapy for post-menopausal women, who are particularly susceptible to the condition.
Hormones have been associated with an increased risk of cancer of the breast and uterus.